Next-Generation Sequencing Identifies Novel RTK VUSs in Breast Cancer with an Emphasis on ROS1, ERBB4, ALK and NTRK3

Pathol Oncol Res. 2020 Jan;26(1):593-595. doi: 10.1007/s12253-018-0550-1. Epub 2018 Nov 20.

Authors

Matthew K Stein^{1

2}, Lindsay K Morris³, Mike G Martin⁴

Affiliations

¹ West Cancer Center, Memphis, TN, USA. mkstein@westclinic.com.
² University of Tennessee Health Science Center, Memphis, TN, USA. mkstein@westclinic.com.
³ College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
⁴ West Cancer Center, Memphis, TN, USA.

PMID: 30460540
DOI: 10.1007/s12253-018-0550-1

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Anaplastic Lymphoma Kinase / chemistry
Anaplastic Lymphoma Kinase / genetics
Breast Neoplasms / genetics*
Breast Neoplasms / pathology
Female
Gene Frequency
Humans
Middle Aged
Mutation
Protein Domains
Protein-Tyrosine Kinases / chemistry
Protein-Tyrosine Kinases / genetics
Proto-Oncogene Proteins / chemistry
Proto-Oncogene Proteins / genetics
Receptor Protein-Tyrosine Kinases / chemistry
Receptor Protein-Tyrosine Kinases / genetics*
Receptor, ErbB-4 / chemistry
Receptor, ErbB-4 / genetics
Receptor, trkC / chemistry
Receptor, trkC / genetics

Substances

NTRK3 protein, human
Proto-Oncogene Proteins
ALK protein, human
Anaplastic Lymphoma Kinase
ERBB4 protein, human
Protein-Tyrosine Kinases
ROS1 protein, human
Receptor Protein-Tyrosine Kinases
Receptor, ErbB-4
Receptor, trkC